Srinivas Akkaraju - 21 Dec 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Director
Signature: /s/ Srinivas Akkaraju
Issuer symbol: SYRS
Transactions as of: 21 Dec 2023
Net transactions value: +$3,999,998
Form type: 4
Filing time: 26 Dec 2023, 17:24:30 UTC
Previous filing: 13 Nov 2023
Next filing: 14 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Purchase	$3,999,998	+904,977	+103%	$4.42	1,786,427	21 Dec 2023	By Samsara BioCapital, L.P.	F1
holding	SYRS	Common Stock						2,666	21 Dec 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.

Content

Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.